Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,018 Mln
P/E Ratio
24.68
P/B Ratio
5.19
Industry P/E
--
Debt to Equity
0.01
ROE
0.25 %
ROCE
22.04 %
Div. Yield
0 %
Book Value
1.29
EPS
0.28
CFO
$163.46 Mln
EBITDA
$126.33 Mln
Net Profit
$53.79 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
MiMedx Group (MDXG)
| -28.17 | -14.69 | -21.39 | 7.47 | 18.15 | 12.76 | -3.44 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
MiMedx Group (MDXG)
| 9.61 | 215.47 | -53.97 | -33.48 | 19.79 | 323.46 | -85.65 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary... PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia. Read more
General Counsel & Chief Administrative Officer
Mr. William F. Hulse IV
General Counsel & Chief Administrative Officer
Mr. William F. Hulse IV
Headquarters
Marietta, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of MiMedx Group Inc (MDXG) stood at $ 264 Mln as on 31-Dec-24
The share price of MiMedx Group Inc (MDXG) is $6.91 (NASDAQ) as of 25-Apr-2025 16:00 EDT. MiMedx Group Inc (MDXG) has given a return of 18.15% in the last 3 years.
MiMedx Group Inc (MDXG) has a market capitalisation of $ 1,018 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of MiMedx Group Inc (MDXG) is 24.68 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the MiMedx Group Inc (MDXG) and enter the required number of quantities and click on buy to purchase the shares of MiMedx Group Inc (MDXG).
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
The CEO & director of Mr. William F. Hulse IV. is MiMedx Group Inc (MDXG), and CFO & Sr. VP is Mr. William F. Hulse IV.
There is no promoter pledging in MiMedx Group Inc (MDXG).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| MiMedx Group Inc (MDXG) | Ratios |
|---|---|
|
Return on equity(%)
|
25.26
|
|
Operating margin(%)
|
16.71
|
|
Net Margin(%)
|
12.16
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of MiMedx Group Inc (MDXG) was $0 Mln.
$0.11
(
